SWM
VVOS icon

SeaCrest Wealth Management’s Vivos Therapeutics VVOS Stock Holding History

SeaCrest Wealth Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,600
Closed -$26K – 666
2022
Q3 		$26K Buy
+1,600
New +$48.7K ﹤0.01% 617

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AF
Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SeaCrest Wealth Management's VVOS Position: Q4 2022 in Review

SeaCrest Wealth Management sold out of Vivos Therapeutics (VVOS) in Q4 2022, closing a stake of 1,600 shares — an estimated $26K sold.

SeaCrest Wealth Management first reported a position in VVOS in Q3 2022 and held it in 1 quarter. The position peaked at $26K in Q3 2022. 27 funds tracked by Wall St. Rank hold VVOS as of Q4 2022.

  • SeaCrest Wealth Management reported no remaining Vivos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • SeaCrest Wealth Management sold 1,600 Vivos Therapeutics shares in Q4 2022, an estimated $26K.
  • SeaCrest Wealth Management first reported a position in Vivos Therapeutics in Q3 2022 and held it in 1 quarter.
  • SeaCrest Wealth Management's Vivos Therapeutics position peaked at $26K in Q3 2022.
  • 27 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2022.

Based on SeaCrest Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2023.